A detailed history of C M Bidwell & Associates LTD transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, C M Bidwell & Associates LTD holds 10 shares of VRTX stock, worth $4,081. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10
Previous 10 -0.0%
Holding current value
$4,081
Previous $4,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$407.69 - $446.08 $382,820 - $418,869
-939 Reduced 98.95%
10 $4,000
Q3 2023

Nov 13, 2023

SELL
$338.18 - $362.46 $7,101 - $7,611
-21 Reduced 2.16%
949 $330,000
Q2 2023

Aug 11, 2023

BUY
$314.42 - $351.91 $212,233 - $237,539
675 Added 228.81%
970 $341,000
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $78,041 - $87,076
285 Added 2850.0%
295 $85,000
Q1 2021

May 14, 2021

SELL
$207.02 - $241.31 $138,910 - $161,919
-671 Reduced 98.53%
10 $2,000
Q4 2020

Feb 16, 2021

SELL
$207.01 - $276.09 $8,073 - $10,767
-39 Reduced 5.42%
681 $161,000
Q3 2020

Nov 13, 2020

SELL
$255.65 - $303.1 $227,272 - $269,455
-889 Reduced 55.25%
720 $196,000
Q2 2020

Aug 14, 2020

SELL
$225.48 - $295.8 $245,998 - $322,717
-1,091 Reduced 40.41%
1,609 $467,000
Q1 2020

May 15, 2020

BUY
$199.77 - $247.81 $273,085 - $338,756
1,367 Added 102.55%
2,700 $642,000
Q4 2019

Feb 12, 2020

BUY
$166.71 - $223.91 $4,167 - $5,597
25 Added 1.91%
1,333 $292,000
Q3 2019

Nov 13, 2019

BUY
$166.23 - $187.09 $215,766 - $242,842
1,298 Added 12980.0%
1,308 $222,000
Q2 2017

Aug 14, 2017

BUY
N/A
10
10 $1,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track C M Bidwell & Associates LTD Portfolio

Follow C M Bidwell & Associates LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of C M Bidwell & Associates LTD, based on Form 13F filings with the SEC.

News

Stay updated on C M Bidwell & Associates LTD with notifications on news.